Showing results (181-190 of 228) with videos related to

Sort By:
Pageof 23
Studies in Health Technology and Informatics|December 8, 1997
International surgical telementoring: our initial experienceB R Lee, J A Caddedu, G Janetschek, et al.
The Journal of Urology|August 8, 2001
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomyE T Goluboff, D Prager, D Rukstalis, et al.
Urology|February 1, 1995
Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volumeA W Partin, S R Criley, M S Steiner, et al.
Medical and Pediatric Oncology|January 1, 1993
The use of nuclear morphometry to predict prognosis in pediatric urologic malignancies: a reviewA W Partin, J P Gearhart, M P Leonard, et al.
Urology|March 1, 1997
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosisH B Carter, A W Partin, A A Luderer, et al.
Urology|December 31, 1997
Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteinsA W Partin, J V Briggman, E N Subong, et al.
Electrophoresis|December 28, 1999
Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet-WebGelP F Lemkin, J M Myrick, Y Lakshmanan, et al.
Hybridoma|January 8, 2000
Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassayT J Wang, H J Linton, J Payne, et al.
JAMA|May 14, 1997
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updateA W Partin, M W Kattan, E N Subong, et al.
The Journal of Urology|April 1, 1990
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasiaA W Partin, H B Carter, D W Chan, et al.
Pageof 23